3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Paraganglioma
6
Meningioma
6
Pheochromocytoma
5
Neuroendocrine Tumors
4
Neuroblastoma
3
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Hypertension
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esthesioneuroblastoma, Olfactory
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Medullary
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Cyclophosphamide
10
Temozolomide
8
X-Rays
7
Specimen Handling
7
Irinotecan
7
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Filgrastim
6
Carboplatin
5
Biopsy
5
fludarabine
4
Nuclear Medicine Department, Hospital
4
olaparib
3
fludarabine phosphate
3
etoposide phosphate
3
dinutuximab
3
Zoledronic Acid
3
Oxaliplatin
3
Nivolumab
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Etoposide
3
Docetaxel
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
lorukafusp alfa
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Osteosarcoma
×
lutetium Lu 177 dotatate
×
CNS
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled